Were the Rapport Therapeutics (RAPP) share sales made under a Rule 10b5-1 trading plan?

Yes. The explanation states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024 .

Rapport Therapeutics (RAPP) CSO sells stock under Rule 10b5-1 plan

Q: What insider transaction did Rapport Therapeutics (RAPP) disclose in this filing?

The filing shows that the Chief Scientific Officer of Rapport Therapeutics, Inc. sold 7,704 shares of common stock at a weighted average price of $29.9469 and 796 shares at a weighted average price of $30.6772 on 12/15/2025 .

Q: Who is the reporting person and what is their role at Rapport Therapeutics (RAPP)?

The reporting person is an officer of Rapport Therapeutics, Inc. , serving as the company’s Chief Scientific Officer .

Q: Is this Rapport Therapeutics (RAPP) filing made by one or multiple reporting persons?

The document indicates that the form is filed by one reporting person , not by more than one reporting person.

Q: What price ranges applied to the Rapport Therapeutics (RAPP) stock sales?

For the 7,704 shares, the filing notes sales at prices ranging from $29.58 to $30.57 . For the 796 shares, prices ranged from $30.61 to $30.72 , with each line item reported as a weighted average.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. reported that its Chief Scientific Officer, who is an officer of the company, sold common stock on 12/15/2025. The transactions involved sales of 7,704 shares at a weighted average price of $29.9469 and 796 shares at a weighted average price of $30.6772, both coded as open-market sales.

These sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. Following the reported transactions, the officer directly beneficially owns 392,642 shares of Rapport Therapeutics common stock.

Insider Trade Summary

Net Seller: 8,500 shares ($255,130)

Net Sell 2 txns

Insider Bredt David

Role Chief Scientific Officer

Sold 8,500 shs ($255K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,704	$29.9469	$231K
Sale	Common Stock	796	$30.6772	$24K

Holdings After Transaction: Common Stock — 393,438 shares (Direct)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.58 to $30.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.61 to $30.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Form 4 Insider Transactions: What Each Field Means →

12/16/2025 - 05:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bredt David

(Last)

(First)

(Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON

02110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/15/2025		S⁽¹⁾		7,704	D	$29.9469⁽²⁾	393,438	D
Common Stock	12/15/2025		S⁽¹⁾		796	D	$30.6772⁽³⁾	392,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.58 to $30.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.61 to $30.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Rapport Therapeutics (RAPP) disclose in this filing?

The filing shows that the Chief Scientific Officer of Rapport Therapeutics, Inc. sold 7,704 shares of common stock at a weighted average price of $29.9469 and 796 shares at a weighted average price of $30.6772 on 12/15/2025.

Who is the reporting person and what is their role at Rapport Therapeutics (RAPP)?

The reporting person is an officer of Rapport Therapeutics, Inc., serving as the company’s Chief Scientific Officer.

How many Rapport Therapeutics (RAPP) shares does the officer own after the sale?

After the reported transactions, the officer beneficially owns 392,642 shares of Rapport Therapeutics common stock directly.

Is this Rapport Therapeutics (RAPP) filing made by one or multiple reporting persons?

The document indicates that the form is filed by one reporting person, not by more than one reporting person.

What price ranges applied to the Rapport Therapeutics (RAPP) stock sales?

For the 7,704 shares, the filing notes sales at prices ranging from $29.58 to $30.57. For the 796 shares, prices ranged from $30.61 to $30.72, with each line item reported as a weighted average.